海翔药业：连续3日股价涨幅偏离值累计超20%，说明情况

Group 1 - The company's stock experienced an abnormal fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days on February 6, 9, and 10, 2026 [1] - As of February 10, the company has repurchased a total of 14.3153 million shares, accounting for 0.8844% of the total share capital, with a transaction amount of 88.8813 million yuan [1] - The company’s investment partnership completed the transfer of unlisted shares of Fuhong Hanlin to H-shares, which were listed on the Hong Kong Stock Exchange on February 4 [1] Group 2 - The company projects a net profit for the fiscal year 2025 to be between -135 million yuan and -90 million yuan, with a non-recurring net profit expected to be between -142 million yuan and -95 million yuan [1]